Search

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

Boehringer Ingelheim shares updated 2030 environmental sustainability commitments

Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients

Life forward - Boehringer Ingelheim unveils its evolved company brand

Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners

Working at Boehringer Ingelheim

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot

• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer Ingelheim increases commitments to sustainable development

Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario

Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers